Not TB-500: the mandatory disambiguation
This is the single highest-priority correction in any thymosin alpha-1 course.
Same prefix, different molecule, different everything
This is the single highest-priority correction in any thymosin alpha-1 course. Peptide-community content constantly treats Tα1 and TB-500 as interchangeable, when TB-500 is a fragment of thymosin beta-4, a structurally and functionally unrelated peptide. Conflating them is a factual error with real consequences.
This unit lays the two side by side: different length, different parent, different mechanism, different clinical use, and different anti-doping status. The only thing they share is a historical name and the crude thymus extract both were first separated from.
Key terms
Why the two get confused
The confusion is entirely a naming accident. Both peptides were first characterized as separate activities in the same crude thymosin fraction 5, and both kept the "thymosin" prefix. From there, marketing collapsed two very different molecules into one fuzzy "thymosin" category.
Read the rows and the pattern is obvious: different length, different parent, different job. There is no sense in which one is a "version" of the other. The word they share describes where they were first found, not what they do.
AdvancedA review that spends a section on this
The point is important enough that the comprehensive Dominari 2020 review carries a section heading of its own for it, setting thymosin alpha-1 against thymosin beta-4. When a formal literature review has to stop and separate two molecules under a heading, it is a strong signal that the conflation is both common and consequential, which is exactly why this course gives it a full unit.